Stanley Jordan
Cedars-Sinai Medical Center · Cedars-Sinai Medical Center Comprehensive Transplant Center · Department of Pediatrics, Cedars-Sinai Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stanley Jordan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06919003 · Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)National Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant · study chair
- Ph1/Ph2NCT03380377 · Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney TransplantStanley Jordan, MD · completed · Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy · principal investigator
- Ph1/Ph2NCT03380962 · Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal TransplantStanley Jordan, MD · completed · Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy · principal investigator
- Ph1/Ph2NCT01594424 · A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney TransplantationCedars-Sinai Medical Center · completed · End Stage Renal Disease (ESRD) · principal investigator
- Ph1/Ph2NCT01178216 · Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney TransplantationStanley Jordan, MD · completed · End Stage Renal Disease · principal investigator
- Ph3NCT00000935 · An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant AntigensNational Institute of Allergy and Infectious Diseases (NIAID) · completed · End-Stage Renal Disease, Kidney Transplantation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationU01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2025 to 2026 · $2,216,525 awarded in 2026Same name and institution; not confirmed by an ID
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationR01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2024 · $2,216,525 awarded in 2024Same name and institution; not confirmed by an ID
- MODIFICATION OF ALLOIMMUNITY BY IVIG IN ESRD PATIENTSU01AI040129 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 1996 to 1999 · $441,667 awarded in 1999Same name and institution; not confirmed by an ID
- IV IG MODULATION OF ALLOIMMUNE RESPONSES IN VIVOU01AI037313 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 1994 to 1998 · $250,000 awarded in 1998Same name and institution; not confirmed by an ID
- CYTOKINE M RNA TRANSCRIPTION BY CELLS INFILTRATING LUNG ALLOGRAFTSS07RR005468 · NCRR · CEDARS-SINAI MEDICAL CENTER · fiscal years 1987 to 1991Same name and institution; not confirmed by an ID
- ANTI-IDIOTYPIC ANTIBODIES IN PRE-TRANSPLANT TRANSFUSIONSR01DK038831 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1986 to 1987 · $157,326 awarded in 1987Same name and institution; not confirmed by an ID
- INDUCTION OF ANTIDIOTYPIC ANTIBODIES BY PRE-TRANSPLANTK04DK001783 · NIDDK · CEDARS-SINAI MEDICAL CENTER · fiscal years 1986 to 1987 · $53,827 awarded in 1987Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:22 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Rituximab and intravenous immune globulin for desensitization during renal transplantation.N Engl J Med · 2008548 citationsRCR 15.3
- Targeted Muscle Reinnervation Treats Neuroma and Phantom Pain in Major Limb Amputees: A Randomized Clinical Trial.Ann Surg · 2019387 citationsRCR 28.9
- Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.J Am Soc Nephrol · 2004344 citationsRCR 9.2
- 292 citationsRCR 12.8
- IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.N Engl J Med · 2017282 citationsRCR 10.6
- Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma.Am J Respir Crit Care Med · 1994261 citationsRCR 8.2
- The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.Kidney Int · 1996216 citationsRCR 6.3
- Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.J Am Soc Nephrol · 1999186 citationsRCR 4.5
- A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.Transplantation · 2015150 citationsRCR 5.5
- A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.Transplantation · 2015122 citationsRCR 4.7